Fruquintinib, a new-comer among anti angiogenetic drug, is a highly selective, long-term small molecule which selectively inhibits VEGFR, which has showed promising results in trials leading to it being recommended in some countries as a third-line agent for the treatment of patients with CRC [78]. This evidence concerns the gene KDR and colorectal carcinoma.